SCHEDULE: Balyasny Asset Management Discloses 7.41% Stake in Opus Genetics

Balyasny Asset Management and its affiliates have reported a 7.41% beneficial ownership stake in Opus Genetics Inc., totaling 5,110,373 shares.

Summary

• Balyasny Asset Management L.P. and its affiliated entities (BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny) have reported beneficial ownership of 5,110,373 shares of Opus Genetics Inc. common stock.
• This represents approximately 7.41% of Opus Genetics Inc.'s outstanding common stock, based on 68,964,208 shares outstanding as of November 10, 2025.
• The reported ownership includes 2,718,029 common shares and 2,392,344 shares issuable upon the exercise of warrants.
• The warrants are subject to a beneficial ownership limitation, preventing exercise if it would result in ownership exceeding 9.99% of the outstanding shares.
• The shares are held directly by Atlas Diversified Master Fund, Ltd. (ADMF), an investment management client of Balyasny Asset Management L.P.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Opus Genetics Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development for Opus Genetics Inc., as it signals a significant vote of confidence from a reputable institutional investor, Balyasny Asset Management, which could attract further investor attention.

Positives

• A significant institutional investor, Balyasny Asset Management, has taken a substantial 7.41% stake in Opus Genetics Inc., indicating confidence in the company's prospects.
• The investment includes both common shares and warrants, suggesting a long-term interest and potential for increased ownership up to the 9.99% beneficial ownership limitation.

Risks

• The beneficial ownership limitation on the warrants (9.99%) restricts the immediate ability of Balyasny Asset Management to increase its stake beyond this threshold through warrant exercise, potentially limiting its influence or further investment flexibility.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Opus Genetics Inc.'s future performance or strategic direction. It solely reports beneficial ownership.

Management Comments

• To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that a significant stake taken by a prominent hedge fund like Balyasny Asset Management in a company like Opus Genetics Inc. (likely in the biotechnology or pharmaceutical sector given the "Genetics" in the name) can often be interpreted as a vote of confidence. Such investments can attract further institutional interest, especially in sectors requiring substantial capital and long development cycles.

Comparison to Industry Standards

• StockSavvy.ai observes that a 7.41% stake is a substantial passive investment for an institutional fund, positioning Balyasny Asset Management as a significant shareholder.
• While not an activist stake (as certified by the 13G filing), it is comparable to the initial positions taken by other large funds in emerging biotech companies, such as the early investments by Perceptive Advisors or RA Capital Management in promising gene therapy or rare disease firms.
• For instance, a similar percentage stake was observed when Baker Bros. Advisors initiated positions in companies like Incyte or Seattle Genetics during their growth phases, signaling strong conviction in the underlying science or market potential.

Related Party Transactions

• Atlas Diversified Master Fund, Ltd. (ADMF), an investment management client of Balyasny Asset Management L.P., is the direct holder of the reported securities and has the right to receive dividends and proceeds from their sale.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may increase investor confidence and potentially lead to positive share price movement.
• Company Management: The presence of a large, passive institutional investor may provide a degree of stability and validation for the company's strategy, though without direct influence on control.

Key Dates

Recommendation

While the significant stake by Balyasny Asset Management is a positive signal, a Schedule 13G filing primarily discloses ownership and does not provide new operational or financial performance data for Opus Genetics Inc. Investors should hold their positions and await further company-specific news or financial reports to make more informed decisions, as this filing alone does not warrant a strong buy or sell recommendation.

Keywords

Opus Genetics Inc., Balyasny Asset Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Warrants, Equity Stake, Investment, SEC Filing